Company: APM
Filing Date: 2025-10-14
Form Type: 424B5
Source: 0001213900-25-098635
Chunk: 13

Company: Aptorum Group Ltd
Filing Date: 2025-10-14
Form: 424B5
Chunk 13
---
 known as Community-Associated
MRSA (“CA-MRSA”), has occurred in wider community among healthy people. It often begins as a painful skin boil and spreads
by skin-to-skin contact. About 85% of serious, invasive MRSA infections are healthcare associated infections (https://www.cdc.gov/media/pressrel/2007/r071016.htm).
The incidence of CA-MRSA varies according to population and geographic location. In the U.S., more than 94,000 people develop serious
MRSA infection and about 19,000 patients die asva result each year (https://www.cdc.gov/media/pressrel/2007/r071016.htm). According
to the US Centers for Disease Control and Prevention (“CDC”), Staphylococcus aureus, including MRSA, caused about 11% of healthcare-associated
infections in 2011 (source: http://www.healthcommunities.com/mrsa-infection/incidence.shtml). Each year in the U.S., around one
out of every twenty-five hospitalized patients contract at least one infection in the hospital (N Engl J Med. 2014, 27;370(13):1198-208).
In the U.S., there were over 80,000 invasive MRSA infections and 11,285 related deaths in 2011 (source: https://edition.cnn.com/2013/06/28/us/mrsa-fast-facts/index.html).
Indeed, severe MRSA infections most commonly occur during or soon after inpatient medical care. More than 290,000 hospitalized patients
are infected with Staphylococcus aureus and of these staphylococcal infections, approximately 126,000 are related to MRSA (source: http://www.healthcommunities.com/mrsa-infection/incidence.shtml).

ALS-4 is a small drug molecule
which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium
in the body or that cause damage to the body’s systems. These products of bacterial genes are referred to as “virulence expression.”
Targeting bacterial virulence is an alternative approach to antimicrobial therapy that offers promising opportunities to overcome the
emergence and increasing prevalence of antibiotic-resistant bacteria.

Professor Richard Kao from
The University of Hong Kong (who is also the Founder and Principal Investigator of Acticule and Inventor of ALS-1, ALS-2, ALS-3 and
ALS-4) initiated a high throughput